切除不能肝細胞がんの市場：全身治療、エンドユーザー別-2025-2030年の世界予測

切除不能肝細胞がん市場は、2023年に16億8,000万米ドルと評価され、2024年には19億米ドルに達すると予測され、CAGR 13.38％で成長し、2030年には40億5,000万米ドルになると予測されています。

切除不能肝細胞がん（uHCC）とは、腫瘍の大きさ、部位、患者の健康状態などの要因により、外科的に切除することができない肝臓がんを指します。肝炎感染、アルコール摂取、非アルコール性脂肪性肝疾患などの要因と結びついた世界の肝臓がん罹患率の増加により、この市場の範囲は拡大しています。治療は、患者の寿命とQOLを向上させる必要性から必要とされ、多くの場合、免疫療法、標的薬、分子阻害剤などの全身療法が関与しており、病院環境と専門的ながん治療センターの両方で実質的に使用されています。これらの治療に対する需要は、新薬発見の精巧さ、ヘルスケア支出の増加、診断技術の向上が原動力となっています。しかし、高い治療費、限定的な償還シナリオ、現行療法に伴う重大な副作用が市場成長の課題となっています。重要な成長要因のひとつは、個別化治療アプローチに多大な可能性を提供するプレシジョン・メディシンの進展です。特に、併用療法の開発や、個々の治療計画を調整するための人工知能の活用に治療機会があります。企業は、治療効果を高めるために大規模な臨床試験に投資し、技術統合のための戦略的提携を模索すべきです。一方、規制上のハードル、倫理的な懸念、より包括的な患者データの必要性が依然として限界として残っています。これらの課題を克服し市場成長を促進するためには、より効果的なバイオマーカー同定と新規ドラッグデリバリーシステムの研究が必要です。一方、地域的な市場拡大は、ヘルスケア資金が増加している新興経済圏を取り込むことで成功する可能性があります。市場の競合情勢は依然激しく、かつ有望であり、イノベーションに意欲的で規制状況を効果的にナビゲートできる企業にとっては、大きな成長の見込みがあります。

市場力学：急速に進化する切除不能肝細胞がん市場の主要市場インサイトを公開

切除不能肝細胞がん市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 高い肝がん罹患率
  • 肝がん患者の増加
  • 化学療法の主な用途
• 市場抑制要因
  • 切除不能肝細胞がんの限定的な診断
• 市場機会
  • 新たな治療法の進歩
• 市場の課題
  • 現在の治療薬の限られた効果

ポーターの5つの力切除不能肝細胞がん市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：切除不能肝細胞がん市場における外部からの影響の把握

外部マクロ環境要因は、切除不能肝細胞がん市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析切除不能肝細胞がん市場における競合情勢の把握

切除不能肝細胞がん市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス切除不能肝細胞がん市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、切除不能肝細胞がん市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨切除不能肝細胞がん市場における成功への道筋を描く

切除不能肝細胞がん市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 肝臓がんの発生率が高い
    • 肝臓がんの増加
    • 化学療法の主な応用
  • 抑制要因
    • 切除不能肝細胞がんの限定診断
  • 機会
    • 新しい治療と療法の進歩
  • 課題
    • 現在の治療法の限界効果
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 切除不能肝細胞がんの市場全身治療別

• 化学療法
• 免疫療法
• 分子標的療法

第7章 切除不能肝細胞がんの市場：エンドユーザー別

• がんセンター
• 病院
• 調査機関
• 専門クリニック

第8章 南北アメリカの切除不能肝細胞がんの市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の切除不能肝細胞がんの市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの切除不能肝細胞がんの市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Astrazeneca PLC
• Bayer AG
• Bristol-Myers Squibb Company
• Celgene Corporation
• Chugai Pharmaceutical Co. Ltd
• Eisai Co. Ltd
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• Glaxosmithkline PLC
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
• Pharmaxis Ltd
• Sanofi S.A.
• Sumitomo Dainippon Pharma Co., Ltd

LIST OF FIGURES

• FIGURE 1. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET RESEARCH PROCESS
• FIGURE 2. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET DYNAMICS
• TABLE 7. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MOLECULARLY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 19. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 20. ARGENTINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 21. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 22. BRAZIL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 23. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 24. CANADA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 25. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 26. MEXICO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 27. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 28. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 29. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 30. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 31. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 32. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 33. AUSTRALIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 34. AUSTRALIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 35. CHINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 36. CHINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 37. INDIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 38. INDIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 39. INDONESIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 40. INDONESIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 41. JAPAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 42. JAPAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 43. MALAYSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 44. MALAYSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 45. PHILIPPINES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 46. PHILIPPINES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 47. SINGAPORE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 48. SINGAPORE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 49. SOUTH KOREA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 50. SOUTH KOREA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 51. TAIWAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 52. TAIWAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 53. THAILAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 54. THAILAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 55. VIETNAM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 56. VIETNAM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 57. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 58. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 59. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 60. DENMARK UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 61. DENMARK UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 62. EGYPT UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 63. EGYPT UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 64. FINLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 65. FINLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 66. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 67. FRANCE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 68. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 69. GERMANY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 70. ISRAEL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 71. ISRAEL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 72. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 73. ITALY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 74. NETHERLANDS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 75. NETHERLANDS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 76. NIGERIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 77. NIGERIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 78. NORWAY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 79. NORWAY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 80. POLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 81. POLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 82. QATAR UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 83. QATAR UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 84. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 85. RUSSIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 86. SAUDI ARABIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 87. SAUDI ARABIA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 90. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 91. SPAIN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 92. SWEDEN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 93. SWEDEN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 94. SWITZERLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 95. SWITZERLAND UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 96. TURKEY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 97. TURKEY UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 98. UNITED ARAB EMIRATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 99. UNITED ARAB EMIRATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 100. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC TREATMENT, 2018-2030 (USD MILLION)
• TABLE 101. UNITED KINGDOM UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 102. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 103. UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET, FPNV POSITIONING MATRIX, 2023

The Unresectable Hepatocellular Carcinoma Market was valued at USD 1.68 billion in 2023, expected to reach USD 1.90 billion in 2024, and is projected to grow at a CAGR of 13.38%, to USD 4.05 billion by 2030.

Unresectable Hepatocellular Carcinoma (uHCC) refers to a form of liver cancer that cannot be surgically removed due to factors like tumor size, location, or patient health. This market's scope has grown due to increasing global liver cancer incidence tied to factors such as hepatitis infections, alcohol consumption, and non-alcoholic fatty liver disease. Treatments are necessitated by the need to improve patient longevity and quality of life, often involving systemic therapies like immunotherapy, targeted drugs, and molecular inhibitors, which represent substantial use within both hospital settings and specialized cancer treatment centers. The demand for these treatments is driven by the sophistication of new drug discoveries, increasing healthcare expenditure, and improving diagnostic techniques. However, market growth is challenged by high treatment costs, limited reimbursement scenarios, and significant side effects associated with current therapies. One key growth factor is the ongoing advancements in precision medicine, which offer tremendous potential for personalized treatment approaches. Opportunities lie particularly in the development of combination therapies and the use of Artificial Intelligence to tailor individual treatment plans. Companies should invest in extensive clinical trials to enhance treatment efficacy and seek strategic partnerships for technology integration. Meanwhile, regulatory hurdles, ethical concerns, and the need for more comprehensive patient data remain as limitations. To overcome these challenges and foster market growth, there's a need for research into more effective biomarker identification and novel drug delivery systems. Meanwhile, regional market expansion could thrive by tapping into emerging economies with increasing healthcare funding. The market's nature remains highly competitive yet promising, with significant growth prospects for enterprises willing to innovate and navigate the regulatory landscape effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Unresectable Hepatocellular Carcinoma Market

The Unresectable Hepatocellular Carcinoma Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • High incidence rate of liver carcinoma
  • Increasing cases of liver cancer
  • Major application of chemotherapy
• Market Restraints
  • Limited diagnosis of unresectable hepatocellular carcinoma
• Market Opportunities
  • Advancements for new treatment and therapies
• Market Challenges
  • Limited effects of current therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the Unresectable Hepatocellular Carcinoma Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Unresectable Hepatocellular Carcinoma Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Unresectable Hepatocellular Carcinoma Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Unresectable Hepatocellular Carcinoma Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Unresectable Hepatocellular Carcinoma Market

A detailed market share analysis in the Unresectable Hepatocellular Carcinoma Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Unresectable Hepatocellular Carcinoma Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Unresectable Hepatocellular Carcinoma Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Unresectable Hepatocellular Carcinoma Market

A strategic analysis of the Unresectable Hepatocellular Carcinoma Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Unresectable Hepatocellular Carcinoma Market, highlighting leading vendors and their innovative profiles. These include Astrazeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Chugai Pharmaceutical Co. Ltd, Eisai Co. Ltd, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Glaxosmithkline PLC, Merck & Co. Inc., Novartis AG, Pfizer Inc., Pharmaxis Ltd, Sanofi S.A., and Sumitomo Dainippon Pharma Co., Ltd.

Market Segmentation & Coverage

This research report categorizes the Unresectable Hepatocellular Carcinoma Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Systemic Treatment, market is studied across Chemotherapy, Immunotherapy, and Molecularly Targeted Therapy.
• Based on End User, market is studied across Cancer Centers, Hospitals, Research institutes, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. High incidence rate of liver carcinoma
    • 5.1.1.2. Increasing cases of liver cancer
    • 5.1.1.3. Major application of chemotherapy
  • 5.1.2. Restraints
    • 5.1.2.1. Limited diagnosis of unresectable hepatocellular carcinoma
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements for new treatment and therapies
  • 5.1.4. Challenges
    • 5.1.4.1. Limited effects of current therapeutics
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Unresectable Hepatocellular Carcinoma Market, by Systemic Treatment

• 6.1. Introduction
• 6.2. Chemotherapy
• 6.3. Immunotherapy
• 6.4. Molecularly Targeted Therapy

7. Unresectable Hepatocellular Carcinoma Market, by End User

• 7.1. Introduction
• 7.2. Cancer Centers
• 7.3. Hospitals
• 7.4. Research institutes
• 7.5. Specialty Clinics

8. Americas Unresectable Hepatocellular Carcinoma Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Unresectable Hepatocellular Carcinoma Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Unresectable Hepatocellular Carcinoma Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Astrazeneca PLC
• 2. Bayer AG
• 3. Bristol-Myers Squibb Company
• 4. Celgene Corporation
• 5. Chugai Pharmaceutical Co. Ltd
• 6. Eisai Co. Ltd
• 7. Eli Lilly and Company
• 8. F. Hoffmann-La Roche Ltd
• 9. Glaxosmithkline PLC
• 10. Merck & Co. Inc.
• 11. Novartis AG
• 12. Pfizer Inc.
• 13. Pharmaxis Ltd
• 14. Sanofi S.A.
• 15. Sumitomo Dainippon Pharma Co., Ltd